176 related articles for article (PubMed ID: 12220505)
1. Inhibition of MEPE cleavage by Phex.
Guo R; Rowe PS; Liu S; Simpson LG; Xiao ZS; Quarles LD
Biochem Biophys Res Commun; 2002 Sep; 297(1):38-45. PubMed ID: 12220505
[TBL] [Abstract][Full Text] [Related]
2. MEPE-ASARM peptides control extracellular matrix mineralization by binding to hydroxyapatite: an inhibition regulated by PHEX cleavage of ASARM.
Addison WN; Nakano Y; Loisel T; Crine P; McKee MD
J Bone Miner Res; 2008 Oct; 23(10):1638-49. PubMed ID: 18597632
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity.
Liu S; Rowe PS; Vierthaler L; Zhou J; Quarles LD
J Endocrinol; 2007 Jan; 192(1):261-7. PubMed ID: 17210763
[TBL] [Abstract][Full Text] [Related]
4. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP).
Rowe PS; Garrett IR; Schwarz PM; Carnes DL; Lafer EM; Mundy GR; Gutierrez GE
Bone; 2005 Jan; 36(1):33-46. PubMed ID: 15664000
[TBL] [Abstract][Full Text] [Related]
5. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization.
Quarles LD
Am J Physiol Endocrinol Metab; 2003 Jul; 285(1):E1-9. PubMed ID: 12791601
[TBL] [Abstract][Full Text] [Related]
6. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP.
Martin A; David V; Laurence JS; Schwarz PM; Lafer EM; Hedge AM; Rowe PS
Endocrinology; 2008 Apr; 149(4):1757-72. PubMed ID: 18162525
[TBL] [Abstract][Full Text] [Related]
7. Analysis of recombinant Phex: an endopeptidase in search of a substrate.
Guo R; Liu S; Spurney RF; Quarles LD
Am J Physiol Endocrinol Metab; 2001 Oct; 281(4):E837-47. PubMed ID: 11551862
[TBL] [Abstract][Full Text] [Related]
8. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
9. The wrickkened pathways of FGF23, MEPE and PHEX.
Rowe PS
Crit Rev Oral Biol Med; 2004 Sep; 15(5):264-81. PubMed ID: 15470265
[TBL] [Abstract][Full Text] [Related]
10. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia.
Liu S; Brown TA; Zhou J; Xiao ZS; Awad H; Guilak F; Quarles LD
J Am Soc Nephrol; 2005 Jun; 16(6):1645-53. PubMed ID: 15843468
[TBL] [Abstract][Full Text] [Related]
11. Defective Mineralization in X-Linked Hypophosphatemia Dental Pulp Cell Cultures.
Coyac BR; Hoac B; Chafey P; Falgayrac G; Slimani L; Rowe PS; Penel G; Linglart A; McKee MD; Chaussain C; Bardet C
J Dent Res; 2018 Feb; 97(2):184-191. PubMed ID: 28880715
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.
Atkins GJ; Rowe PS; Lim HP; Welldon KJ; Ormsby R; Wijenayaka AR; Zelenchuk L; Evdokiou A; Findlay DM
J Bone Miner Res; 2011 Jul; 26(7):1425-36. PubMed ID: 21312267
[TBL] [Abstract][Full Text] [Related]
13. Active sites of human MEPE-ASARM regulating bone matrix mineralization.
Minamizaki T; Sakurai K; Hayashi I; Toshishige M; Yoshioka H; Kozai K; Yoshiko Y
Mol Cell Endocrinol; 2020 Nov; 517():110931. PubMed ID: 32712387
[TBL] [Abstract][Full Text] [Related]
14. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia.
Barros NM; Hoac B; Neves RL; Addison WN; Assis DM; Murshed M; Carmona AK; McKee MD
J Bone Miner Res; 2013 Mar; 28(3):688-99. PubMed ID: 22991293
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage.
Addison WN; Masica DL; Gray JJ; McKee MD
J Bone Miner Res; 2010 Apr; 25(4):695-705. PubMed ID: 19775205
[TBL] [Abstract][Full Text] [Related]
16. Abnormal presence of the matrix extracellular phosphoglycoprotein-derived acidic serine- and aspartate-rich motif peptide in human hypophosphatemic dentin.
Boukpessi T; Gaucher C; Léger T; Salmon B; Le Faouder J; Willig C; Rowe PS; Garabédian M; Meilhac O; Chaussain C
Am J Pathol; 2010 Aug; 177(2):803-12. PubMed ID: 20581062
[TBL] [Abstract][Full Text] [Related]
17. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX.
Liu S; Guo R; Simpson LG; Xiao ZS; Burnham CE; Quarles LD
J Biol Chem; 2003 Sep; 278(39):37419-26. PubMed ID: 12874285
[TBL] [Abstract][Full Text] [Related]
18. Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone.
Argiro L; Desbarats M; Glorieux FH; Ecarot B
Genomics; 2001 Jun; 74(3):342-51. PubMed ID: 11414762
[TBL] [Abstract][Full Text] [Related]
19. Age dependent regulation of bone-mass and renal function by the MEPE ASARM-motif.
Zelenchuk LV; Hedge AM; Rowe PS
Bone; 2015 Oct; 79():131-42. PubMed ID: 26051469
[TBL] [Abstract][Full Text] [Related]
20. Abnormal osteopontin and matrix extracellular phosphoglycoprotein localization, and odontoblast differentiation, in X-linked hypophosphatemic teeth.
Salmon B; Bardet C; Coyac BR; Baroukh B; Naji J; Rowe PS; Opsahl Vital S; Linglart A; Mckee MD; Chaussain C
Connect Tissue Res; 2014 Aug; 55 Suppl 1():79-82. PubMed ID: 25158186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]